Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group

被引：2

作者：

Motomura, Kazuya ^{[1
]}

Sasaki, Keita ^{[2
]}

Sugii, Narushi ^{[3
]}

Yamaguchi, Shigeru ^{[4
]}

Inoue, Hirotaka ^{[5
]}

Oshima, Akito ^{[6
]}

Tanaka, Kazuhiro ^{[7
]}

Otani, Yoshihiro ^{[8
]}

Shirahata, Mitsuaki ^{[9
]}

Shibahara, Ichiyo ^{[10
]}

Nagane, Motoo ^{[11
]}

Tsuzuki, Shunsuke ^{[12
]}

Matsutani, Tomoo ^{[13
]}

Tsukamoto, Yoshihiro ^{[14
]}

Kijima, Noriyuki ^{[15
]}

Asano, Kenichiro ^{[16
]}

Ohno, Makoto ^{[17
]}

Inoue, Akihiro ^{[18
]}

Mineharu, Yohei ^{[19
]}

Miyake, Keisuke ^{[20
]}

Mitobe, Yuta ^{[21
]}

Hanihara, Mitsuto ^{[22
]}

Kawanishi, Yu ^{[23
]}

Deguchi, Shoichi ^{[24
]}

Saito, Masato ^{[25
]}

Matsuda, Ryosuke ^{[26
]}

Ujifuku, Kenta ^{[27
]}

Arita, Hideyuki ^{[28
]}

Sato, Yuichi ^{[29
]}

Yamashita, Shinji ^{[30
]}

Yonezawa, Ushio ^{[31
]}

Yamaguchi, Junya ^{[1
]}

Momii, Yasutomo ^{[32
]}

Ogawa, Takahiro ^{[33
]}

Kambe, Atsushi ^{[34
]}

Ohba, Shigeo ^{[35
]}

Fukai, Junya ^{[36
]}

Saito, Norihiko ^{[37
]}

Kinoshita, Masashi ^{[38
]}

Sumi, Koichiro ^{[39
]}

Otani, Ryohei ^{[40
]}

Uzuka, Takeo ^{[41
]}

Takebe, Noriyoshi ^{[42
]}

Koizumi, Shinichiro ^{[43
]}

Saito, Ryuta ^{[1
]}

Arakawa, Yoshiki ^{[19
]}

Narita, Yoshitaka ^{[17
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Neurosurg, 65 Tsurumai Co,Showa Ku, Nagoya, Japan

[2] JCOG Data Ctr, Natl Canc Ctr Hosp, Operat Off, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

[3] Univ Tsukuba Hosp, Dept Neurosurg, 2-1-1 Amakubo, Tsukuba, Japan

[4] Hokkaido Univ, Fac Med, Dept Neurosurg, North 15,West 7,Kita Ku, Sapporo, Japan

[5] Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, 1-1-1,Honjo,Chuo Ku, Kumamoto, Japan

[6] Yokohama City Univ, Dept Neurosurg, 3-9 Fukuura, Kanazawa, Yokohama, Japan

[7] Kobe Univ Hosp, Dept Neurosurg, 7-5-1 Kusunoki Cho,Chuo Ku, Kobe, Japan

[8] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Dept Neurol Surg, 2-5-1 Shikata Cho,Kita Ku, Okayama, Japan

[9] Med Univ Int Med Ctr, Dept Neurosurg Neurooncol, 1397-1 Yamane,Hidaka, Saitama, Saitama, Japan

[10] Kitasato Univ, Dept Neurosurg, Sch Med, 1-15-1,Minami Ku,Sagamihara, Kitasato, Japan

[11] Kyorin Univ, Fac Med, Dept Neurosurg, 6-20-2 Shinkawa, Tokyo, Japan

[12] Tokyo Womens Med Univ, Dept Neurosurg, 8-1 Kawada-Cho,Shinjuku Ku, Tokyo, Japan

[13] Chiba Univ, Grad Sch Med, Dept Neurol Surg, 1-8-1 Inohana,Chuou Ku, Chiba, Japan

[14] Niigata Univ, Brain Res Inst, Dept Neurosurg, 1-757 Asahimachi Dori,Chuo Ku, Niigata, Japan

[15] Osaka Univ, Grad Sch Med, Dept Neurosurg, 2-2 Yamadaoka,Suita, Osaka, Japan

[16] Hirosaki Univ, Grad Sch Med, Dept Neurosurg, Zaifu Cho 5, Hirosaki, Japan

[17] Natl Canc Ctr, Dept Neurosurg & Neurooncol, 5-1-1 Tsukiji,Chuo Ku, Tokyo, Japan

[18] Ehime Uunivers, Sch Med, Dept Neurosurg, 454 Shitsukawa, Toon, Ehime, Japan

[19] Kyoto Univ, Grad Sch Med, Dept Neurosurg, 54 Kawahara Cho,Shogoin Sakyo Ku, Kyoto, Japan

[20] Kagawa Univ, Fac Med, Dept Neurol Surg, 1750-1 Ikenobe,Miki Cho, Kagawa, Japan

[21] Yamagata Univ Hosp, Dept Neurosurg, 2-2-2 Iida-Nishi, Yamagata, Japan

[22] Univ Yamanashi, Dept Neurosurg, 1110 Shimokato, Kofu, Yamanashi, Japan

[23] Kochi Univ, Kochi Med Sch, Dept Neurosurg, Oko Cho,Nanko Ku, Kohasu, Kochi, Japan

[24] Shizuoka Canc Ctr, Dept Neurosurg, Shimonagakubo 1007, Nagaizumi, Shizuoka, Japan

[25] Asahikawa Med Univ, Dept Neurosurg, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Japan

[26] Nara Med Univ, Dept Neurosurg, Shijo Cho 840, Kashihara, Nara, Japan

[27] Nagasaki Univ, Grad Sch Biomed Sci, Dept Neurosurg, 1-7-1 Sakamoto, Nagasaki, Japan

[28] Osaka Int Canc Inst, Dept Neurosurg, 3-1-69, Otemae, Chuo Ku, Osaka, Japan

[29] Iwate Med Univ, Sch Med, Dept Neurosurg, 2-1-1 Idai Dori, Shiwa, Iwate, Japan

[30] Miyazaki Univ, Dept Neurosurg, 5200 Kihara Kiyotake, Miyazaki, Japan

[31] Hiroshima Univ Hosp, Dept Neurosurg, 1-2-3 Minami Ku, Kasumi, Hiroshima, Japan

[32] Oita Univ, Fac Med, Dept Neurosurg, 1-1 Idaigaoka Hasama Machi, Yufu, Oita, Japan

[33] Kyoto Prefectural Univ Med, Dept Neurosurg, 465 Kajii Cho,Kawaramachi-Hirokoji,Kamigyo Ku, Kyoto, Japan

[34] Tottori Univ, Fac Med, Dept Brain & Neurosci, Div Neurosurg, 36-1 Nishi Cho, Yonago, Tottori, Japan

[35] Fujita Hlth Univ, Dept Neurosurg, 1-98 Dengakugakubo,Kutsukake Cho, Toyoake, Aichi, Japan

[36] Wakayama Med Univ, Sch Med, Dept Neurol Surg, 811-1 Kimiidera, Wakayama, Japan

[37] Toho Univ, Ohashi Med Ctr, Dept Neurosurg, 2-22-36 Ohashi, Meguro, Tokyo, Japan

[38] Kanazawa Univ, Dept Neurosurg, 13-1 Takara Machi, Kanazawa, Japan

[39] Nihon Univ, Sch Med, Dept Neurol Surg, 30-1 Oyaguchikamicho,Itabashi Ku, Tokyo, Japan

[40] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Neurosurg, 3-18-22 Honkomagome,Bunkyo Ku, Tokyo, Japan

[41] Dokkyo Med Univ Hosp, Dept Neurosurg, 880 Kitakobayashi,Mibu Machi, Tochigi, Japan

[42] Med Res Inst Kitano Hosp, Dept Neurosurg, PIIF Tazuke Kofukai, 2-4-20 Ohgimachi,Kita-Ku, Osaka, Japan

[43] Hamamatsu Univ Sch Med, Dept Neurosurg, 1-20-1 Handayama,Higashi Ku, Hamamatsu, Shizuoka, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 54卷 / 10期

关键词：

glioblastoma; primary central nervous system lymphoma; treatment regimen; high-cost medical care; cost; HIGH-DOSE METHOTREXATE; RANDOMIZED PHASE-III; CHEMOTHERAPY; TEMOZOLOMIDE; GLIOBLASTOMA; RADIOTHERAPY; TRIAL; BEVACIZUMAB; CONCOMITANT; RITUXIMAB;

D O I：

10.1093/jjco/hyae116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background This study aimed to investigate what treatment are selected for malignant brain tumors, particularly glioblastoma (GBM) and primary central nervous system lymphoma (PCNSL), in real-world Japan and the costs involved.Methods We conducted a questionnaire survey regarding treatment selections for newly diagnosed GBM and PCNSL treated between July 2021 and June 2022 among 47 institutions in the Japan Clinical Oncology Group-Brain Tumor Study Group. We calculated the total cost and cost per month of the initial therapy for newly diagnosed GBM or PCNSL.Results The most used regimen (46.8%) for GBM in patients aged <= 74 years was 'Surgery + radiotherapy concomitant with temozolomide'. This regimen's total cost was 7.50 million JPY (Japanese yen). Adding carmustine wafer implantation (used in 15.0%), TTFields (used in 14.1%), and bevacizumab (BEV) (used in 14.5%) to the standard treatment of GBM increased the cost by 1.24 million JPY for initial treatment, and 1.44 and 0.22 million JPY per month, respectively. Regarding PCNSL, 'Surgery (biopsy) + rituximab, methotrexate, procarbazine, and vincristine (R-MPV) therapy' was the most used regimen (42.5%) for patients of all ages. This regimen incurred 1.07 million JPY per month. The three PCNSL regimens based on R-MPV therapy were in ultra-high-cost medical care (exceeding 1 million JPY per month).Conclusions Treatment of malignant brain tumors is generally expensive, and cost-ineffective treatments such as BEV are frequently used. We believe that the results of this study can be used to design future economic health studies examining the cost-effectiveness of malignant brain tumors. As regimens used in GBM or PCNSL are costly, we believe that it will be necessary in the future to take cost-effectiveness into consideration in selecting a treatment.

引用

页码：1123 / 1131

页数：9

共 50 条

[1] Current Status of Palliative and Terminal Care for Patients with Primary Malignant Brain Tumors in Japan
Aoki, Tomokazu
Narita, Yoshitaka
Mishima, Kazuhiko
Matsutani, Masao
NEUROLOGIA MEDICO-CHIRURGICA, 2020, 60 (12) : 600 - 611
[2] The Activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group
Iwamoto, Yukihide
Tanaka, Kazuhiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (06) : 467 - 470
[3] Atypical and malignant granular cell tumors in Japan: a Japanese Musculoskeletal Oncology Group (JMOG) study
Jungo Imanishi
Yasuo Yazawa
Tsuyoshi Saito
Michio Shimizu
Hiroyuki Kawashima
Keisuke Ae
Akihiko Matsumine
Tomoaki Torigoe
Hideshi Sugiura
Susumu Joyama
International Journal of Clinical Oncology, 2016, 21 : 808 - 816
[4] Atypical and malignant granular cell tumors in Japan: a Japanese Musculoskeletal Oncology Group (JMOG) study
Imanishi, Jungo
Yazawa, Yasuo
Saito, Tsuyoshi
Shimizu, Michio
Kawashima, Hiroyuki
Ae, Keisuke
Matsumine, Akihiko
Torigoe, Tomoaki
Sugiura, Hideshi
Joyama, Susumu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (04) : 808 - 816
[5] Current trend of radiotherapy for glioblastoma in the elderly: a survey study by the brain tumor Committee of the Korean Radiation Oncology Group (KROG 21-05)
Wee, Chan Woo
Yoon, Hong In
Lee, Sea-Won
Lim, Do Hoon
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (08) : 835 - 841
[6] High-cost treatments for advanced lung cancer in Japan (Lung Cancer Study Group of the Japan Clinical Oncology Group)
Watanabe, Kageaki
Sasaki, Keita
Machida, Ryunosuke
Shimizu, Junichi
Yamane, Yuki
Tamiya, Motohiro
Saito, Shin
Takada, Yuji
Yoh, Kiyotaka
Yoshioka, Hiroshige
Murakami, Haruyasu
Kitazono, Satoru
Goto, Yasuhiro
Horinouchi, Hidehito
Ohe, Yuichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (10) : 1084 - 1092
[7] Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study
Nahls, Nelli-Sofia
Leskela, Riikka-Leena
Saarto, Tiina
Hirvonen, Outi
Anttonen, Anu
BMC PALLIATIVE CARE, 2023, 22 (01)
[8] Present clinical practices of stereotactic irradiation for metastatic brain tumors in Japan: results of questionnaire survey of the Japanese Radiation Oncology Study Group (JROSG) working subgroup for neurological tumors
Harada, Ken
Igaki, Hiroshi
Abe, Eisuke
Ariga, Takuro
Hayashi, Nobuyuki
Kanemoto, Ayae
Komiyama, Takafumi
Matsumoto, Yasuo
Nakano, Toshimichi
Onimaru, Rikiya
Saito, Hirotake
Sumi, Minako
Tago, Masao
Tanaka, Kensuke
Maebayashi, Katsuya
Aoyama, Hidefumi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (06) : 1015 - 1022
[9] The History of the Gynecologic Cancer Study Group (GCSG) of the Japan Clinical Oncology Group (JCOG)
Onda, Takashi
Konishi, Ikuo
Yoshikawa, Hiroyuki
Kamura, Toshiharu
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (10) : 1156 - 1161
[10] MGMT Promoter Methylation Is Prognostic but Not Predictive for Outcome to Adjuvant PCV Chemotherapy in Anaplastic Oligodendroglial Tumors: A Report From EORTC Brain Tumor Group Study 26951
van den Bent, Martin J.
Dubbink, Hendrikus J.
Sanson, Marc
van der Lee-Haarloo, Cathleen R.
Hegi, Monika
Jeuken, Judith W. M.
Idbaih, Ahmed
Brandes, Alba A.
Taphoorn, Martin J. B.
Frenay, Marc
Lacombe, Denis
Gorlia, Thierry
Dinjens, Winand N. M.
Kros, Johan M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) : 5881 - 5886

← 1 2 3 4 5 →